[1]Siegel, R., C. Desantis and A. Jemal, Colorectal cancer statistics, 2014. CA Cancer J Clin, 2014. 64(2): p. 104-117. [2]Lee, W.S., et al., Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis, 2007. 22(6): p. 699-704. [3]Van Cutsem, E., et al., Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 2006. 42(14): p. 2212-2221. [4]Yoo, P.S., et al., Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer, 2006. 6(3): p. 202-207. [5]Muratore, A., et al., Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol, 2007. 14(2): p. 766-770. [6]Hayashi, M., et al., Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg, 2010. 10: p. 27. [7]Gervaz, P., et al., Colorectal adenocarcinoma in cirrhotic patients. J Am Coll Surg, 2003. 196(6): p. 874-879. [8]Qiu, H.B., et al., HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World J Gastroenterol, 2011. 17(6): p. 804-808. [9]Utsunomiya, T., et al., Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus. Am J Surg, 1999. 177(4): p. 279-281. [10]Lisa, J.R., C. Solomon and E.J. Gordon, Secondary Carcinoma in Cirrhosis of the Liver. Am J Pathol, 1942. 18(1): p. 137-140. [11]Uetsuji, S., et al., Absence of colorectal cancer metastasis to the cirrhotic liver. Am J Surg, 1992. 164(2): p. 176-177. [12]Seymour, K.and R.M. Charnley, Evidence that metastasis is less common in cirrhotic than normal liver: a systematic review of post-mortem case-control studies. Br J Surg, 1999. 86(10): p. 1237-1242. [13]Uetsuji, S., et al., Absence of colorectal cancer metastasis to the cirrhotic liver. Am J Surg, 1992. 164(2): p. 176-177. [14]Utsunomiya, T., et al., Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus. Am J Surg, 1999. 177(4): p. 279-281. [15]Song, E., et al., Rare occurrence of metastatic colorectal cancers in livers with replicative hepatitis B infection. Am J Surg, 2001. 181(6): p. 529-533. [16]Cui, Y.and J. Jia, Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol, 2013. 28 Suppl 1: p. 7-10. [17]Psaila, B.and D. Lyden, The metastatic niche: adapting the foreign soil. Nat Rev Cancer, 2009. 9(4): p. 285-293. [18]Morgan, S.C. and C.C. Parker, Local treatment of metastatic cancer--killing the seed or disturbing the soil? Nat Rev Clin Oncol, 2011. 8(8): p. 504-506. [19]Sung, S.Y., et al., Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer, 2007. 31(2): p. 36-100. [20]Lisa, J.R., C. Solomon and E.J. Gordon, Secondary Carcinoma in Cirrhosis of the Liver. Am J Pathol, 1942. 18(1): p. 137-140. [21]LIEBER, M.M., The rare occurrence of metastatic carcinoma in the cirrhotic liver. Am J Med Sci, 1957. 233(2): p. 145-152. [22]Hamaya, K., H. Hashimoto and Y. Maeda, Metastatic carcinoma in cirrhotic liver--Statistical survey of autopsies in Japan. Acta Pathol Jpn, 1975. 25(2): p. 153-159. [23]Scoazec, J.Y., Expression of cell-matrix adhesion molecules in the liver and their modulation during fibrosis. J Hepatol, 1995. 22(2 Suppl): p. 20-27. [24]Gervaz, P., et al., Colorectal adenocarcinoma in cirrhotic patients. J Am Coll Surg, 2003. 196(6): p. 874-879. [25]Llorent, L., et al., Cytokine gene expression in cirrhotic and non-cirrhotic human liver. J Hepatol, 1996. 24(5): p. 555-563. [26]Consolo, M., et al., Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med, 2009. 24(2): p. 143-152. [27]Urtasun, R., D.L.R.L. Conde and N. Nieto, Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis, 2008. 12(4): p. 769-790, viii. [28]Badra, G., et al., Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. Acta Microbiol Immunol Hung, 2010. 57(1): p. 29-42. [29]Islekel, H., et al., Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct, 2007. 25(4): p. 433-441. [30]Dunn, G.P., et al., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol, 2002. 3(11): p. 991-998. [31]Schreiber, R.D., L.J. Old and M.J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011. 331(6024): p. 1565-1570. [32]Yoffe, B., et al., Extrahepatic hepatitis B virus DNA sequences in patients with acute hepatitis B infection. Hepatology, 1990. 12(2): p. 187-192. [33]Mason, A., et al., Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology, 1993. 18(4): p. 781-789. [34]Neurath, A.R., et al., Detection of receptors for hepatitis B virus on cells of extrahepatic origin. Virology, 1990. 176(2): p. 448-457. [35]Doherty, D.G., et al., The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol, 1999. 163(4): p. 2314-2321. [36]McDonald, B., et al., Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer, 2009. 125(6): p. 1298-1305. [37]Lara-Pezzi, E., et al., The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology, 1998. 28(4): p. 1013-1021. [38]Song, E., et al., Kupffer cells of cirrhotic rat livers sensitize colon cancer cells to Fas-mediated apoptosis. Br J Cancer, 2001. 84(9): p. 1265-1271. [39]Rushfeldt, C., et al., Early events of hepatic metastasis formation in mice: role of Kupffer and NK-cells in natural and interferon-gamma-stimulated defense. J Surg Res, 1999. 82(2): p. 209-215. [40]Tsujimoto, T., et al., Augmented hepatocellular carcinoma progression and depressed Kupffer cell activity in rat cirrhotic livers. Int J Oncol, 2001. 18(1): p. 41-47. [41]Kaufmann, T., A. Strasser and P.J. Jost, Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ, 2012. 19(1): p. 42-50. [42]Moulian, N., et al., Functional Fas expression in human thymic epithelial cells. Blood, 1999. 93(8): p. 2660-2670. [43]Yang, C., H.Z. Liu and Z.X. Fu, PEG-liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase-8. Cell Biol Int, 2012. 36(3): p. 289-296. [44]McDermott, U., et al., Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res, 2005. 65(19): p. 8951-8960. [45]Li, H., et al., Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology, 2009. 137(3): p. 934-944, 944.e1-4. [46]徐彤, 李强与郝希山, 大肠癌细胞功能性Fas配体的表达度与肿瘤免疫逃逸的关系.世界华人消化杂志, 2004(09): 第56-59页. [47]Thiery, J.P., et al., Epithelial-Mesenchymal Transitions in Development and Disease. Cell, 2009. 139(5): p. 871-890. [48]Thiery, J.P. and J.P. Sleeman, Complex networks orchestrate epithelial–mesenchymal transitions. Nature Reviews Molecular Cell Biology, 2006. 7(2): p. 131-142. [49]Yilmaz, M.and G. Christofori, Mechanisms of Motility in Metastasizing Cells. Molecular Cancer Research, 2010. 8(5): p. 629-642. [50]Hosel, M., et al., Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology, 2009. 50(6): p. 1773-1782. [51]Li, H., et al., Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-beta1 over pro-inflammatory cytokines. Dig Liver Dis, 2012. 44(4): p. 328-333. [52]Hagen, T.M., et al., Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A, 1994. 91(26): p. 12808-1212. [53]You, Q., et al., Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology, 2008. 48(3): p. 978-990. [54]Tordjmann, T., et al., Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Liver, 1998. 18(6): p. 391-397. [55]Yu, H., et al., The contribution of TGF-beta in Epithelial-Mesenchymal Transition (EMT): Down-regulation of E-cadherin via snail. Neoplasma, 2015. 62(1): p. 1-15. [56]Xu, H., et al., Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer, 2014. 14(1): p. 330. [57]Maheswaran, T.and S.M. Rushbrook, Epithelial-mesenchymal transition and the liver: Role in hepatocellular carcinoma and liver fibrosis. Journal of Gastroenterology and Hepatology, 2012. 27(3): p. 418-420. [58]Wallace, K., A.D. Burt and M.C. Wright, Liver fibrosis. Biochemical Journal, 2008. 411(1): p. 1. [59]Liao, Y., et al., Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell Death and Disease, 2014. 5(3): p. e1137. [60]Chen, D., et al., Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology, 2014. 60(2): p. 598-609. [61]Mitchell, P.S., et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences, 2008. 105(30): p. 10513-10518. [62]Yu, F., et al., let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. Cell, 2007. 131(6): p. 1109-1123. [63]Ru, P., et al., miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition Signaling. Molecular Cancer Therapeutics, 2012. 11(5): p. 1166-1173. [64]Huang, Z., et al., Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International Journal of Cancer, 2010. 127(1): p. 118-126. [65]Gregory, P.A., et al., The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 2008. 10(5): p. 593-601. [66]Jackstadt, R., et al., AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. Journal of Experimental Medicine, 2013. 210(7): p. 1331-1350. [67]Shi, L., et al., p53-Induced miR-15a/16-1 and AP4 Form a Double-Negative Feedback Loop to Regulate Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer. Cancer Research, 2014. 74(2): p. 532-542. [68]Wu, F., et al., Targets for human encoded microRNAs in HBV genes. Virus Genes, 2011. 42(2): p. 157-161. [69]Wang, Y., et al., Hepatitis B Viral RNA Directly Mediates Down-regulation of the Tumor Suppressor MicroRNA miR-15a/miR-16-1 in Hepatocytes. Journal of Biological Chemistry, 2013. 288(25): p. 18484-18493. [70]Ura, S., et al., Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology, 2009. 49(4): p. 1098-1112. [71]Murakami, Y., et al., The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families. PLoS ONE, 2011. 6(1): p. e16081. [72]Li, W., et al., The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS Journal, 2011. 278(9): p. 1522-1532.